2seventy bio ( (TSVT) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
2seventy bio, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the time and resources required to negotiate a proposed acquisition by Bristol-Myers Squibb Company and to complete the company’s financial statement close and related reporting processes. The company anticipates filing the report within the fifteen-day extension period allowed by Rule 12b-25. There are no expected significant changes in financial results from the previous year, and the company is committed to maintaining compliance. The notification was signed by Victoria Eatwell, the Chief Financial Officer.
More about 2seventy bio
YTD Price Performance: 67.23%
Average Trading Volume: 1,010,960
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $255.4M
For an in-depth examination of TSVT stock, go to TipRanks’ Stock Analysis page.